Merck expects Keytruda to face HHS price setting in 2026 (MRK:NYSE)


Merck & Co. headquarters in Silicon Valley

Sundry Photography

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act.

In a filing with the SEC, Merck (NYSE:MRK) noted that the U.S. Department


Leave a Comment